FOXD2 and cancer: In laryngeal SCC chemotherapy-resistant patients, FOXD2-AS1 showed increased expression and acted as a scaffold for STAT2 and PRMT5, both essential to maintain cancer stemness and promote chemotherapy resistance (18).